Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer
-
3D Systems Enables First FDA Clearance for Implant from a Point-of-Care Institution
-
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
-
Hubbell Reports Second Quarter 2026 Results
-
PMGC Holdings Inc. Announces Strategic Investment in Precision Aerospace & Defense Group and Long-Term Aerospace and Defense Manufacturing Agreement Through A&B Aerospace Inc.
-
Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET
-
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
-
Judge Consulting Group President and CTO John Battaglia Named to City & State PA’s 2026 “40 in Their 40s” List
-
Judge Consulting Group President and CTO John Battaglia Named to City & State PA’s 2026 “40 in Their 40s” List
-
DCX’s DexTrader Announces Upgrade, Targeting On-Chain Yield-Bearing Collateralized Derivatives Data Services Segment
-
-
Xali Gold Continues to Demonstrate the Scale and Grade of Gold Mineralization at Pico Machay
-
Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder
-
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
-
Dundee Corporation Announces Further Results of Infill Drilling at Westhaven’s Shovelnose Gold and Silver Project, Southern British Columbia
-
Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration
-
Rubicon Organics to Report Q2 2026 Results
-
Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
-
NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026
-
Stingray Provides Update on Management Cease Trade Order
-
Westhaven Reports South Zone Resource Infill Drilling Continues to Confirm Continuity of High-Grade Gold and Silver Mineralization Including 27.51m Grading 14.47 g/t Au & 52 g/t Ag Shovelnose Gold
-
Canadian home prices remain soft - but the story varies significantly outside big metropolitan centers
-
VR Confirms New IP and Conductivity Anomalies on its Bonita Property Porphyry Copper-Gold Project in Nevada
-
Guardian Capital LP Launches Innovative AI Fund
-
Blue Gold Announces Appointment of Andrew Cavaghan as Chairman
-
Interbrand and Clootrack Partner to Launch the Industry’s First AI-Native Brand Experience Operating System
-
SunPower Reports Q2’26 Results
-
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
-
Factorial Sets Date for Second Quarter 2026 Results
-
CSL Marks the Completion of the First Vessel in World-Leading Transhipment Fleet for Simandou Project
-
National Civil Rights Museum Hosts the 2026 Ruby Bridges Reading Festival
-
Lantronix Announces DoD Solution Partnership to Deploy Edge AI Drone Platform in Ukraine
-
Selkirk Copper Mines Inc. Begins Trading on OTCQX Best Market
-
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
-
Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML
-
Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
-
Lungpacer Announces Health Economic Analysis Demonstrating Clinical and Cost Benefits of AeroPace in Mechanically Ventilated Patients
-
Manhattan Bridge Capital, Inc. Declares Quarterly Dividend
-
DoubleDown Interactive to Report 2026 Second Quarter Results on August 11 and Host Conference Call and Webcast
-
Change in Vaisala Corporation’s number of series A and K shares
-
Antag Therapeutics Announces Dosing of First Patient in Phase 2a Trial of First-in-Class GIPR Antagonist AT7687
-
Dimensional Fund Advisors Ltd. : Form 8.3 - Irish Continental Group Plc - Ordinary Shares
-
SNDL Reports Second Quarter 2026 Financial and Operational Results
-
YieldMax® ETFs Announces Weekly Distributions for Group 1 ETFs
-
INNIO wins 1.1 Gigawatt Gas Engine Order for Major Data Center Campus
-
City Electric Supply (CES) reports strong fiscal year results across North America for the seventh consecutive year
-
MEXC Users Put Nearly a Third of First-Month RealStocks Volume Into SpaceX
-
KN Energies and INDEL Corporation Sign Memorandum of Understanding in Vietnam
-
BrowserAct Launches BrowserAct Agent Build: An AI Web Scraper That Builds and Tests Itself From a Single Prompt
-
INNIO Group Reports Second Quarter 2026 Financial Results

